Clinical trial
A Randomized Controlled Single-Blind Investigation to Evaluate the Safety and Performance of the AC5 Topical Hemostatic Device (AC5™) Following Excision of Skin Lesions
NCT02704104 is registered in ClinicalTrials.gov with Arch Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Controlled Single-Blind Investigation to Evaluate the Safety and Performance of the AC5 Topical Hemostatic Device (AC5™) Following Excision of Skin Lesions
- Lead sponsor
- Arch Therapeutics
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- February 29, 2016
- Completion date
- June 30, 2016
- Enrollment
- 46 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.